Octagon Capital Advisors’s Stoke Therapeutics STOK Stock Holding History

Octagon Capital Advisors’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-185,669	Closed	-$1.97M	–	44
2023 Q2	$1.97M	Hold	185,669	–	–	0.27%	34
2023 Q1	$1.55M	Sell	185,669 -577,787	-76%	-$5.21M	0.22%	33
2022 Q4	$7.05M	Hold	763,456	–	–	1.1%	21
2022 Q3	$9.8M	Hold	763,456	–	–	1.69%	14
2022 Q2	$10.1M	Sell	763,456 -50,000	-6%	-$760K	2.69%	8
2022 Q1	$17.1M	Buy	813,456 +29,687	+4%	+$594K	3.7%	9
2021 Q4	$18.8M	Buy	783,769 +486,947	+164%	+$11.6M	3.66%	9
2021 Q3	$7.55M	Hold	296,822	–	–	1.86%	16
2021 Q2	$9.99M	Buy	+296,822	New	+$10.5M	2.07%	16

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Octagon Capital Advisors's STOK Position: Q3 2023 in Review

Octagon Capital Advisors sold out of Stoke Therapeutics (STOK) in Q3 2023, closing a stake of 185,669 shares — an estimated $1.97M sold.

Octagon Capital Advisors first reported a position in STOK in Q2 2021 and held it in 9 quarters. The position peaked at $18.8M in Q4 2021. 96 funds tracked by Wall St. Rank hold STOK as of Q3 2023.

Octagon Capital Advisors reported no remaining Stoke Therapeutics position as of Q3 2023 after selling out during the quarter.
Octagon Capital Advisors sold 185,669 Stoke Therapeutics shares in Q3 2023, an estimated $1.97M.
Octagon Capital Advisors first reported a position in Stoke Therapeutics in Q2 2021 and held it in 9 quarters.
Octagon Capital Advisors's Stoke Therapeutics position peaked at $18.8M in Q4 2021.
96 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2023.

Based on Octagon Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.